Researchers have investigated a toxin–antitoxin system in tuberculosis as a therapeutic target, providing the first high-resolution details.
Browsing: Bacterial > Tuberculosis
New data analysis of three clinical trials has suggested that a precision medicine approach could allow some pulmonary TB patients to have significantly shorter treatment periods.
On the day of UNGA’s first-ever high-level meeting on tuberculosis we summarize the key points from the WHO 2018 Global Tuberculosis Report and what this meeting could mean for accelerating progress.
A study using standardized patients has reported that private practitioners in India are delivering a wide range of often inadequate care to tuberculosis patients.
Scientists at the University of Manchester (UK) have developed the first non-antibiotic drug to successfully treat tuberculosis (TB) in animal…
Financial modelling has been used to estimate the costs and likelihood of candidate medicines, vaccines, diagnostics and technologies launching, revealing gaps in the pipeline and in funding.
Clinical trial data has proved a novel, short therapy more effective and safe for the treatment of latent tuberculosis than the standard therapy in both adults and children.
Guy Thwaites, Director of the Oxford University Clinical Research Unit/Wellcome Program in Vietnam, speaks on neurotuberculosis and the challenges it faces in terms of treatment, HIV co-infection and the political will necessary for change.
Take a look behind the science of a recent Future Microbiology article, entitled ‘Better than a pound of cure: preventing the development of multidrug-resistant tuberculosis’ as we ask the authors about the challenges currently facing multidrug resistant (MDR) tuberculosis and what the future might hold.
World Tuberculosis Day 2018 (March 24th) is an annual event aiming to raise public awareness around the health, economic and…